129 related articles for article (PubMed ID: 7700478)
1. Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors.
Nakagawa K; Kamezaki T; Shibata Y; Tsunoda T; Meguro K; Nose T
Neurol Med Chir (Tokyo); 1995 Jan; 35(1):22-7. PubMed ID: 7700478
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
Merchant RE; Grant AJ; Merchant LH; Young HF
Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
[TBL] [Abstract][Full Text] [Related]
3. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
4. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.
Merchant RE; Merchant LH; Cook SH; McVicar DW; Young HF
Neurosurgery; 1988 Dec; 23(6):725-32. PubMed ID: 2851116
[TBL] [Abstract][Full Text] [Related]
5. Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients.
Ibayashi Y; Yamaki T; Kawahara T; Daibo M; Kubota T; Uede T; Tanabe S; Hashi K
Neurol Med Chir (Tokyo); 1993 Jul; 33(7):448-57. PubMed ID: 7692323
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
[TBL] [Abstract][Full Text] [Related]
7. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
8. [Recurrence with tumor bleeding in a patient with malignant astrocytoma during the treatment with intracranial injection of lymphokine-activated killer cells--a case report].
Nagane M; Oyama H; Shibui S; Nomura K
No To Shinkei; 1993 Jun; 45(6):547-51. PubMed ID: 8395864
[TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
11. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
[TBL] [Abstract][Full Text] [Related]
13. The cellular immunotherapy of primary brain tumors.
Hayes RL
Rev Neurol (Paris); 1992; 148(6-7):454-66. PubMed ID: 1448666
[TBL] [Abstract][Full Text] [Related]
14. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients.
Cascinelli N; Belli F; Marchini S; Marolda R; Prada A; Sciorelli G; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G
Tumori; 1989 Jun; 75(3):233-44. PubMed ID: 2788945
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.
Lillehei KO; Mitchell DH; Johnson SD; McCleary EL; Kruse CA
Neurosurgery; 1991 Jan; 28(1):16-23. PubMed ID: 1994273
[TBL] [Abstract][Full Text] [Related]
18. Regional administration of lymphokine-activated killer cells can be superior to intravenous application.
Keilholz U; Schlag P; Tilgen W; Brado B; Galm F; Görich J; Kauffmann GW; Möller P; Schneider S; Hunstein W
Cancer; 1992 Apr; 69(8):2172-5. PubMed ID: 1544123
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH; Sznol M; Mier J; Sparano J; Fisher RI; Weiss G
J Clin Oncol; 1991 Apr; 9(4):641-8. PubMed ID: 2066760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
